期刊文献+

药物临床应用风险因果模型的构建与探讨 被引量:1

Establishment and Discussion of the Drug Utility Related Risk Causal Model
下载PDF
导出
摘要 目的构建和探讨适用于药物临床应用风险事件的风险因果模型。方法对本文立论相关风险理论、药物治疗学论著进行了归纳、分析。结果和结论风险因素、风险事件和风险损害是风险发生的三大要素,复杂系统中风险促发因素和风险拦截因素也十分重要,上述要素共同组成风险发生因果模型。风险因果模型移植药物应用过程可见:药物固有特性对应风险因素,是大多用药的风险事件和损害的本因;医务工作者药物诊疗计划的制定和执行、患者生理心理状态均是风险促发因素;正式的规章制度、操作规程和散在的感知和沟通构成药物应用中风险拦截因素。药物临床应用风险发生因果模型可以帮助正确认识用药风险来源、正视风险事件和发生过程,对于药物应用管理措施设计具有促进作用。 Objective To establish and discuss the drug utility related risk causal model. Methods The works concerning the foundation of this article, namely risk theory and pharmacotherapeutics, were summarized and analyzed. Results & Conclusion Hazard, loss, peril were the three key elements of risk, they constituted the causal model together with contributory and intercept factors, which took important role in complex system. In the view of causal model, the drug characters were the hazard, which contributed most drug related peril and loss. The contributory factors included the healthcare staff's clinical decision and related implementation, as well as the condition of the patients. The regulation, SOPs and individual experience, perception and communication were acted as intercept factors. The casual model would give rise to the acknowledgement of the drug related risk source, process, which would enhance drug utility management.
出处 《中国药物警戒》 2013年第9期549-552,556,共5页 Chinese Journal of Pharmacovigilance
关键词 药物 临床应用 风险 drug clinical use risk
  • 相关文献

参考文献21

  • 1Van Boxtel C J, Santoso B, Edwards I R. Drug benefits and risks:international textbook of clinical pharmacology [M]. Amsterdam:IOS Press, 2008:6.
  • 2Uhl K, Trontell A, Kennedy D. Risk minimization practices forpregnancy prevention: understanding risk, selecting tools[J]. Pharm-acoepidemiology And Drug Safety,2007,16(3): 337-348.
  • 3Castaneda C P, Zeldis J B, Freeman J, et al. RevAssist[J]. Drug Safety,2008,31(9): 743-752.
  • 4Carroll J S. Incident reviews in high-hazard industries: sense makingand learning under ambiguity and accountability [J] .Organization& Environment, 1995, 9(2): 175-197.
  • 5La Porte T R, Rochlin G. A rejoinder to Perrow[J]. Journal of Conti-ngencies and Crisis Management, 1994, 2(4): 221-227.
  • 6Manley M T. Incidence, contributory factors and costs of pressuresores [J]. South African Medical Journal, 1978, 53(6): 217-222.
  • 7Vincent C, Taylor A S, Chapman E J, et al. How to investigate andanalyse clinical incidents: clinical risk unit and association of liti-gation and risk management protocol [J]. British Medical Journal,2000, 320(7237): 777-781.
  • 8Tighe C M, Woloshynowych M,Brown R, et al. Incident report-ing in one UK accident and emergency department [J]. AccidentAnd Emergency Nursing, 2006, 14(1): 27-37.
  • 9Vincent C, Taylor A S,Chapman E J, et al. How to investigateand analyse clinical incidents: clinical risk unit and association oflitigation and risk management protocol [J]. British Medical Journal,2000, 320(7237): 777.
  • 10Reason J. Human error: models and management [J]. British Med-ical Journal, 2000, 320(7237): 768.

二级参考文献29

  • 1李崇剑,周宪梁,张沛,王国干,朱俊,高润霖.静脉用胺碘酮致严重肝功能损害一例[J].中华心律失常学杂志,2004,8(4):251-251. 被引量:10
  • 2汪芳,李一石.胺碘酮的临床药理及其应用进展[J].中国医刊,2006,41(2):28-31. 被引量:74
  • 3Chow MS.Intravenous amiodarone.Pharmacolony,pharmaco-kinetics and clinical use[J].Ann Pharmacother,1996,30(6):637-643.
  • 4Mason JW. Amiodarone[J]. N Engl J Med, 1987, 316(8):455-466.
  • 5McGovem B, Garan H, Kelly E, et al. Adverse reactions during treatment with amiodarone hydrochloride [J].BMJ, 1983, 287(6386):175-180.
  • 6Harris L, McKenna WJ, Rowland E, et al. Side effects of long-term amiodarone therapy[J]. Circulation, 1983, 67(1):45-51.
  • 7Fogoros RN, Anderson KP, Winkle RA, et al. Amiodarone: clinical efficacy and toxicity in 96 patients with recurrent, drug-refractory arrhythmias [J]. Circulation 1983, 68(1):88-94.
  • 8Rhodes A, Eastwood JB, Smith SA. Early acute hepatitis with parenteral amiodarone: A toxic effect of the vehicle? [J]. Gut 1993, 34(4):565-566.
  • 9Pye M, Northcote RJ, Cobbe SM. Acute hepatitis alter parenteral amiodarone administration [J]. Br Heart J 1988, 59(6):690-691.
  • 10Gregory SA, Webster JB, Chapman GD. Acute hepatitis induced by parenteral amiodarone[J]. Am J Med 2002,Med 2002, 113(15):254-255.

共引文献77

同被引文献8

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部